0.00
—
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Virpax Pharmaceuticals
Its shares trade under the ticker VRPX. It has been listed since 17 February 2021.
Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. The company is headquartered in Berwyn, Pennsylvania. The company went IPO on 2021-02-17. The firm is focused on developing novel and drug delivery systems. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, PES200, AnQlar and NobrXiol. Probudur is a drug product candidate based on a liposomal delivery system utilizing large multi-vesicular vesicles (LMVVs) encapsulating a high dose of the local anesthetic bupivacaine. PES200 enables the delivery of a metabolically labile peptide drug (Enkephalin) into the brain for post-traumatic stress disorder. NobrXiol is being developed by Nanomerics as an investigational formulation delivered via the nasal route to enhance Cannabidiol transport to the brain.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 17 Feb 2021
- Employees
- 7
- Website
- virpaxpharma.com ↗
Leadership
Pay as last reported
- Mr. Jatinder DhaliwalChief Executive Officer, Director
- Dr. Sheila MathiasChief Scientific Officer$498,000
- Mr. Michael DubinIndependent Director$65,600
- Dr. Thani JambulingamIndependent Director$76,200
- Dr. Barbara RuskinIndependent Director$63,750
- Mr. Jerrold SendrowIndependent Director$73,550
- Ms. Betsy BrodInvestor Relations, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Virpax Pharmaceuticals focuses on non-addictive pain management products for patients.
- The company employs seven full-time staff members in Berwyn, Pennsylvania.
- Probudur utilizes liposomal delivery systems for high-dose local anesthetic bupivacaine.
Weaknesses
- The firm operates at a preclinical stage with limited product candidates.
- Virpax Pharmaceuticals has only seven employees to manage development efforts.
- Multiple candidates like Envelta and PES200 remain in early development phases.
Opportunities
- NobrXiol offers nasal delivery routes to enhance Cannabidiol transp for CNS disorders.
- PES200 enables delivery of Enkephalin into the brain for post-traumatic stress disorder.
- Developing novel drug delivery systems can advance non-opioid pain management treatments.
Threats
- Preclinical stage status means no approved products generate revenue yet.
- Competition in the pharmaceutical sector may hinder market entry for candidates.
- Regulatory hurdles could delay the approval of AnQlar and other candidates.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.